Lineage Cell Therapeutics
(NYSEMKT) LCTX
Lineage Cell Therapeutics Financials at a Glance
Market Cap
$386.09M
Revenue (TTM)
$14.56M
Net Income (TTM)
$63.53M
EPS (TTM)
$-0.28
P/E Ratio
-5.57
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$1.52
Volume
704,089.266
Open
$1.53
Price
$1.52
Volume
704,089.266
Open
$1.53
Previous Close
$1.53
Daily Range
$1.51 - $1.57
52-Week Range
$0.37 - $2.09
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$1.52
Volume
704,089.266
Open
$1.53
Previous Close
$1.53
Daily Range
$1.51 - $1.57
52-Week Range
$0.37 - $2.09
LCTX News
LCTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Lineage Cell Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
77
CEO
Brian M. Culley, MBA
Website
www.lineagecell.comHeadquarters
Carlsbad, CA 92008, US
LCTX Financials
Key Financial Metrics (TTM)
Gross Margin
94%
Operating Margin
-1%
Net Income Margin
-4%
Return on Equity
-103%
Return on Capital
-22%
Return on Assets
-56%
Earnings Yield
-17.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$386.09M
Shares Outstanding
249.09M
Volume
704.09K
Short Interest
0.00%
Avg. Volume
1.17M
Financials (TTM)
Gross Profit
$13.71M
Operating Income
$21.78M
EBITDA
$21.08M
Operating Cash Flow
$18.92M
Capital Expenditure
$522.00K
Free Cash Flow
$19.44M
Cash & ST Invst.
$55.78M
Total Debt
$2.42M
Lineage Cell Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.61M
+130.4%
Gross Profit
$5.84M
+115.3%
Gross Margin
88.42%
N/A
Market Cap
$386.09M
N/A
Market Cap/Employee
$5.52M
N/A
Employees
70
N/A
Net Income
$851.00K
+126.0%
EBITDA
$19.60M
+495.3%
Quarterly Fundamentals
Net Cash
$53.36M
+17.8%
Accounts Receivable
$1.56M
+144.8%
Inventory
$0.00
N/A
Long Term Debt
$1.57M
+15.0%
Short Term Debt
$853.00K
-26.0%
Return on Assets
-56.43%
N/A
Return on Invested Capital
-21.52%
N/A
Free Cash Flow
$4.99M
+25.7%
Operating Cash Flow
$4.88M
+23.1%